Details for Patent: 8,771,648

« Back to Dashboard

Which drugs does patent 8,771,648 protect, and when does it expire?

Patent 8,771,648 protects TAVALISSE and is included in one NDA.

This patent has thirty-three patent family members in twenty-seven countries.

Summary for Patent: 8,771,648

Title:	(Trimethoxyphenylamino) pyrimidinyl formulations
Abstract:	There are provided pharmaceutical compositions comprising greater than 15% w/w of a compound of Formula (I) as defined herein and/or hydrate thereof and an amount of one or more effervescent agents that is sufficient to provide satisfactory in vitro dissolution; and further comprising one or more pharmaceutically acceptable ingredients; and to processes for obtaining them.
Inventor(s):	Bindhumadhavan GURURAJAN, Farhan Abdul Karim ALHUSBAN, Ian Paul GABBOTT, David Bradley Brook Simpson, Dawn SIEVWRIGHT
Assignee:	Rigel Pharmaceuticals Inc
Application Number:	US13/559,805
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,771,648
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 8,771,648

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Rigel Pharms	TAVALISSE	fostamatinib disodium	TABLET;ORAL	209299-001	Apr 17, 2018	AB	RX	Yes	No			Y
Rigel Pharms	TAVALISSE	fostamatinib disodium	TABLET;ORAL	209299-002	Apr 17, 2018	AB	RX	Yes	Yes			Y

International Family Members for US Patent 8,771,648

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	087371
Australia	2012288632
Brazil	112014001999
Canada	2843138
China	103826610
Cyprus	1122596
Denmark	2736487